Tigecycline

• CAT Number: A000675
• CAS Number: 220620-09-7
• Molecular Formula: C29H39N5O8
• Molecular Weight: 585.7
• Purity: ≥95%
• Target: Antibiotic
• Solubility: >29.3mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: (4S,4aS,5aR,12aR)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
• InChI: InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,40,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1
• InChIKey: SOVUOXKZCCAWOJ-HJYUBDRYSA-N
• SMILES: CC(C)(C)NCC(=O)NC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C

Tigecycline(CAS 220620-09-7) is the first commercially available member of the glycylcyclines, is a new class of antimicrobial agents. It is prepared by the introduction of a tert-butylaminoacetamido group into a previously unexplored and un-substituted region of existing tetracyclines; Tigecycline acts by reversibly binding to the 30S ribosomal subunit; inhibits protein translation by blocking entry of aminoacyl-trna into the ribosome A site;

 

 

 

 

Overview of Clinical Research

Tigecycline is an antibacterial by inhibiting mitochondrial protein. 

Reference

1: Jha BK, Seo I, Kong HH, Suh SI, Suh MH, Baek WK. Tigecycline inhibits proliferation of Acanthamoeba castellanii. Parasitol Res. 2015 Mar;114(3):1189-95. doi: 10.1007/s00436-014-4302-1. Epub 2015 Jan 7. PubMed PMID: 25563616.
2: Kaewpoowat Q, Ostrosky-Zeichner L. Tigecycline : a critical safety review. Expert Opin Drug Saf. 2015 Feb;14(2):335-42. doi: 10.1517/14740338.2015.997206. Epub 2014 Dec 25. Review. PubMed PMID: 25539800.
3: Thomas A, Khan F, Uddin N, Wallace MR. Tigecycline for severe Clostridium difficile infection. Int J Infect Dis. 2014 Sep;26:171-2. doi: 10.1016/j.ijid.2014.04.025. Epub 2014 Jul 23. PubMed PMID: 25064460.
4: McGovern PC, Wible M, Korth-Bradley JM, Quintana A. Pancreatitis in tigecycline Phase 3 and 4 clinical studies. J Antimicrob Chemother. 2014 Mar;69(3):773-8. doi: 10.1093/jac/dkt427. Epub 2013 Nov 11. PubMed PMID: 24216769; PubMed Central PMCID: PMC3922153.
5: Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1459-70. doi: 10.1517/17425255.2011.623126. Epub 2011 Sep 30. Review. PubMed PMID: 21958044.